Last reviewed · How we verify

NCT06151379

Muscle Parameters and Pathological Response in Breast Cancer Patients

Completed Last updated 30 November 2023
What this trial tests

trial testing Neoadjuvant therapy in Neoadjuvant Chemotherapy in 69 participants. Completed in 20 October 2023.

Timeline
1 March 2023
Primary endpoint
30 September 2023
20 October 2023

Quick facts

Lead sponsorAcıbadem Atunizade Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment69
Start date1 March 2023
Primary completion30 September 2023
Estimated completion20 October 2023
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Acıbadem Atunizade Hospital

Who can join

Adults 29 to 72, female only, with Neoadjuvant Chemotherapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators aimed to accurately measure muscle mass and predict pCR to NAC and its effect on clinical outcomes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Neoadjuvant therapy

Trials testing the same drug.

Other recruiting trials for Neoadjuvant Chemotherapy

Currently open trials in the same condition.

Other Acıbadem Atunizade Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06151379.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing